Cogent Biosciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for COGT, updated each market day.
COGT AI Sentiment
AI sees no strong directional signal for Cogent Biosciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cogent Biosciences, Inc. Common Stock
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Sector
Exchange
Market Cap
$5,865,840,754
Cap Tier
Employees
258
Headquarters
WALTHAM, MA
Listed Since
March 29, 2018
Website
COGT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
COGT Volatility
Cogent Biosciences, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
